Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-alpha intranasal prophylaxis for COVID-19 in cancer patients
ACTRN12620000843954Phase 3Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Dec 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Interferon-alpha intranasal prophylaxis with Placebo intranasal spray (2 arms). Primary endpoints: Incidence of COVID-19 and Incidence of community-acquired respiratory viral infection. Started Dec 2020; status: completed.
02
Drugs
interferon alfa
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12620000843954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000843954.